FDA Adverse Event Malfunction Summary report: N

ACCESS 2 IMMUNOASSAY SYSTEM

MDR report key: 1061499 · Received June 17, 2008

Report

Report Number
2122870-2008-00189
Event Type
Malfunction
Date Received
June 17, 2008
Date of Event
May 24, 2008
Report Date
June 17, 2008
Manufacturer
BECKMAN COULTER, INC.
Product Code
MMI
PMA / PMN Number
K922823/A007
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
ME, US
Reporter Occupation
NO INFORMATION

Narratives

Additional Manufacturer Narrative · 1

QC LEVEL I WAS OUT HIGH IN 2008 BEFORE THE EVENT AND PASSED UPON REPEAT. QC LEVEL III WAS WITHIN SPECIFICATIONS. NO OTHER RESULTS OF ASSAYS WERE QUESTIONED BY THE CUSTOMER. THE LAB POLICY IS TO REPEAT ALL POSITIVE ACCU TNI SAMPLES BEFORE REPORTING THEM OUT OF THE LAB. THE SPECIMEN WAS COLLECTED IN A BD, LITHIUM HEPARIN TUBE AND WAS CENTRIFUGED PER THE MANUFACTURE'S RECOMMENDATIONS. A FIELD SERVICE ENGINEER (FSE) WAS DISPATCHED TO THE CUSTOMER'S LAB: THE FSE CHECKED ALL INTERNAL SYSTEMS AND ALIGNMENTS. THE FSE REPLACED A TRANSDUCER AND ASPIRATE PROBES. THE FSE PERFORMED HARDWARE VERIFICATION PROTOCOL ALONG WITH 50-REPLICATES ACCU TNI RUN. ALL VERIFICATION TESTING PASSED WITHIN SPECIFICATIONS. A CLEAR ROOT CAUSE FOR THIS EVENT HAS NOT BEEN DETERMINED. A MALFUNCTION WILL BE ASSUMED FOR THE PURPOSE OF THIS REPORT.

Description of Event or Problem · 1

A CUSTOMER CONTACTED BECKMAN COULTER INC. (BCI) REGARDING AN ERRONEOUSLY ELEVATED TROPONIN (ACCU TNI) RESULT GENERATED BY THE ACCESS 2 INSTRUMENT FOR ONE PATIENT. A PATIENT SAMPLE WAS TESTED FOR ACCU TNI AND A RESULT OF 1.29NG/ML WAS REPORTED OUT OF THE LAB. THE ORIGINAL SAMPLE WAS RETESTED ON THE NEXT DAY AND REPEATED RESULT WAS 0.03 NG/ML. A CORRECTED REPORT WAS SUBMITTED. NO DEATH, INJURY, OR CHANGE TO PATIENT TREATMENT OCCURED AS A RESULT OF THIS EVENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ACCESS 2 IMMUNOASSAY SYSTEM DISCRETE PHOTOMETRIC CHEMISTRY ANALYZER MMI BECKMAN COULTER, INC. ACCESS 2 IMMUNOASSAY SYSTEM NA

Patients

Seq Age Sex Outcome Treatment
1 NA